ArticleExperimental and therapeutic medicine2017
MicroRNA-338-3p targets SOX4 and inhibits cell proliferation and invasion of renal cell carcinoma.
Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Role of microRNA-363 during tumor progression and invasion.Journal of physiology and biochemistry · 2024Review
- Regulating POLR3G by MicroRNA-26a-5p as a promising therapeutic target of lung cancer stemness and chemosensitivity.Non-coding RNA research · 2023Article
- SPRR3, a novel miR-338-3p target, regulates the malignant progression of clear cell renal cell carcinomaExperimental and therapeutic medicine · 2022Article
- hsa_circ_0001018 promotes papillary thyroid cancer by facilitating cell survival, invasion, GMolecular therapy. Nucleic acids · 2021Article
- Molecular interactions of miR-338 during tumor progression and metastasis.Cellular & molecular biology letters · 2021Review
- The Diagnostic Value of Serum Ang, VEGF, and CRP Combined with the Chinese Medicine Antitumor Formula in the Treatment of Advanced Renal Carcinoma.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Silver nanoparticles achieve cytotoxicity against breast cancer by regulating long-chain noncoding RNA XLOC_006390-mediated pathway.Toxicology research · 2021Article
- LINC02738 Participates in the Development of Kidney Cancer Through the miR-20b/Sox4 Axis.OncoTargets and therapy · 2020Article
- Dysregulation of the miR-25-IMPA2 axis promotes metastatic progression in clear cell renal cell carcinoma.EBioMedicine · 2019Article
- miR-363-3p Inhibits Osteosarcoma Cell Proliferation and Invasion via Targeting SOX4.Oncology research · 2019Article
- Down-regulation of miR-338-3p and Up-regulation of MACC1 Indicated Poor Prognosis of Epithelial Ovarian Cancer Patients.Journal of Cancer · 2019Article
- Kinesin Motor Protein KIFC1 Is a Target Protein of miR-338-3p and Is Associated With Poor Prognosis and Progression of Renal Cell Carcinoma.Oncology research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA (miR)-338-3p has been reported to be involved in tumor progression and development in various types of cancer. However, the biological function of miR-338-3p and its related molecular pathways involved in the progression of renal cell carcinoma (RCC) are unknown. The present study aimed to investigate the biological role and underlying mechanism of miR-338-3p in RCC cells. It was demonstrated that miR-338-3p expression level was significantly downregulated (P<0.05) in RCC tissues and cell lines. Clinical association analysis indicated that low expression of miR-338-3p was significantly associated with advanced TNM stage and lymph node metastasis (P<0.05). Function assays revealed that restoration of miR-338-3p in RCC cells significantly inhibited cell proliferation, colony formation, migration and invasion (P<0.05). Notably, sex-determining region Y-box 4 (SOX4) was identified as a direct target of miR-338-3p in RCC cells through a luciferase reporter assay, reverse transcription-quantitative polymerase chain reaction and western blot analysis. Furthermore, SOX4 overexpression partially rescued miR-338-3p-mediated inhibition of cell proliferation, colony formation, migration and invasion in RCC cells. These results suggested that miR-338-3p functioned as a tumor suppressor in RCC cells by modulating SOX4, suggesting that miR-338-3p may have a potential use in the treatment of RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.